Despite a major new Bitcoin purchase, MicroStrategy's stock has plunged to its lowest level since September 2024, as market turbulence and mixed analyst sentiment pressure the crypto-focused software firm ahead of its earnings report.
While retirement planning often focuses on savings, a critical financial metric—net worth—reveals a more precarious reality for many households. We examine the causes and consequences of negative net worth, offering actionable steps to build a stronger financial foundation.
From a $10 direct listing to a $150 S&P 500 constituent, Palantir's journey has been fueled by the AI boom. As government and commercial demand surge, analysts project staggering growth. But with sky-high valuations, the path forward requires navigating lofty expectations.
Popular, Inc. (BPOP) shares have rallied following robust 2025 results, driven by higher net interest income, EPS growth, and aggressive shareholder returns via dividends and buybacks. With the stock up nearly 20% in 90 days, investors are weighing whether its current valuation still offers an entry point.
Insulet (PODD) shares have faced significant pressure in recent months, diverging from the company's underlying business performance. This analysis delves into whether the current price weakness presents a buying opportunity for the Omnipod maker or reflects deeper market concerns about its premium valuation and growth sustainability.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
New unemployment filings in Wisconsin edged higher last week, contrasting with a slight national decline and highlighting regional economic disparities as labor market signals remain mixed.
Missouri's inaugural month of legal sports betting attracted over $540 million in wagers, but aggressive promotions led to a net revenue loss for operators, even as the state collected millions in fees and taxes.
Axon Enterprise stock fell sharply this week, caught in a sector-wide downturn for software stocks driven by AI disruption fears and valuation concerns, despite a lack of company-specific negative news.
Amidst economic crosscurrents, a closer look at Ideal Power, NetSol Technologies, and Sono-Tek reveals companies executing distinct strategies to navigate growth and profitability challenges in the high-risk, high-reward penny stock arena.
American Express reported fourth-quarter earnings that slightly trailed analyst forecasts, prompting a share price decline. Despite the near-term miss, the company issued strong forward guidance for 2026 and announced a significant dividend hike, underscoring confidence in its long-term growth trajectory driven by card member spending and fee growth.
After soaring to unprecedented highs, copper prices have begun to retreat. Goldman Sachs forecasts a more significant market adjustment by mid-2026, driven by potential U.S. tariff policies and a disconnect from fundamental demand.
Financial planners are urging a shift in mindset: the date on your retirement party invitation matters less than the balance in your investment portfolio. We break down the calculations that show whether you're truly ready to leave the workforce.
A stunning reversal wiped out months of gains for precious metals on Friday, with gold futures tumbling to $4,800 and silver recording a historic single-day drop, sparking fears of a volatile new phase for commodity markets.
New unemployment filings in Wisconsin edged higher last week, diverging from a slight national decline and highlighting ongoing labor market fluctuations across states.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
Despite posting a Q4 net loss, Covenant Logistics signals a shift in market dynamics, with executives pointing to rising spot rates, secured contract increases, and a disciplined fleet strategy as precursors to a stronger performance by late 2026.
While major indices hold steady, a search for growth is turning the spotlight onto smaller companies. We examine three small-cap stocks—from insurance to banking to luxury watches—that are posting strong results and navigating unique challenges in the current market.
Shares of diabetes care innovator Insulet have tumbled nearly 10% year-to-date, sparking a fierce debate among investors. While a key valuation model suggests the stock is deeply undervalued, its sky-high P/E ratio tells a conflicting story. We examine the numbers and what they mean for the future of the Omnipod maker.
